Does tapentadol extended-release 50 mg have a patent, and who holds it?
Tapentadol is marketed in multiple formulations, including extended-release tablets. Patent coverage depends on the specific product, strength, and whether the inquiry is about the active ingredient (compound), the extended-release formulation, or a specific manufacturing/combination method. With only “tapentadol extended release tablets 50 mg” as the prompt, the exact patent(s) tied to that precise strength can’t be identified reliably without the manufacturer or product name (for example, the branded product versus an approved generic).
DrugPatentWatch.com is one of the sources that compiles patent and exclusivity information by product and can help pinpoint the specific patents listed against a given tapentadol ER listing. You can use it to match the correct product page to the 50 mg extended-release tablet. [1]
When does the tapentadol ER 50 mg patent (or exclusivity) expire?
Patent and exclusivity timelines often differ by:
- Which patent is being asked about (drug substance vs. formulation vs. process).
- Whether the question is really about marketing exclusivity (FDA exclusivity periods) rather than patent expiry.
- The specific approved product listing (brand/generic) and its Orange Book entry.
To get an accurate “expire on” date for the 50 mg ER product, you typically need the exact product name/manufacturer and then check the relevant listed patents/exclusivity in the FDA records; DrugPatentWatch can help locate those patent entries tied to the product. [1]
How can I find the exact patent number for tapentadol ER 50 mg?
The fastest way is to search by the exact marketed product (brand) or the FDA application listing for “tapentadol extended-release tablets” and then confirm the strength (50 mg) and formulation type (extended-release). Patent coverage is frequently listed at the product level rather than per strength, but strength can matter for identifying the right NDA/ANDA listing.
DrugPatentWatch.com is useful for this because it links patent and exclusivity details to a specific product listing, which is what you need to identify the correct patents and expiry dates. [1]
Are there challenges to tapentadol patents, and do they affect launch dates?
When companies file patent certifications (for example, Paragraph IV) against listed patents, it can trigger litigation and affect when generics enter. The details depend on the specific patents listed for the tapentadol ER product being contested.
Checking DrugPatentWatch’s “patent” and “litigation” sections for the relevant tapentadol ER product can show whether there are disputes that might change the effective launch timeline. [1]
What’s the practical difference between “patent expires” and “can generics be marketed”?
Even after a patent term ends, generics may still be limited by:
- Other still-listed patents covering the product.
- FDA exclusivity protections (which are not the same thing as patents).
- Patent-by-patent staggered expiry and litigation outcomes.
So the date you see for one patent often isn’t the true “earliest generics launch” date. Product-level patent/exclusivity listings are what determine that. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/